How to choose a pharma commercial analytics platform

Pharma commercial analytics is not one kind of vendor wearing different logos — it's four different business models that all get filed under the same category. A software layer that sits on top of a CRM you already run. A consulting firm that also licenses a platform. A data company selling prescriber and claims data outright. A partner that will run parts of your commercial organization for you. Picking between them by feature comparison alone misses the point: the real decision is which business model matches the gap you actually have.

You need this kind of tool if you are a pharmaceutical or biotech company planning a launch, running a field sales organization, or trying to understand prescriber and market behavior for a brand. You probably don't need it, or need only a narrow piece of it, if you're pre-commercial and years from a launch decision.

Four business models, not one

• Software layer on your CRM. Aktana doesn't replace your CRM/SFA system — it sits on top of Veeva CRM or Salesforce and generates next-best-action suggestions for reps and marketing teams across channels. If you don't already have a mature CRM in place, there's nothing for Aktana to enhance.
• Consulting plus platform. Beghou Consulting and ZS both combine paid consulting engagements with a licensable software platform (Beghou's Mainsail and ARMADA, ZS's ZAIDYN), covering sales-force design, territory alignment, incentive compensation and forecasting. You're buying expertise and a platform together, not just software.
• Data vendor. Symphony Health sells prescription and medical claims data itself — market-share tracking, prescriber-level targeting, brand performance measurement — competing directly with data products like IQVIA's Xponent. You're licensing the underlying dataset, not buying analysis of data you already have.
• Outsourced commercial organization. EVERSANA will run parts of your commercial function directly — field sales deployment, patient services, market access, digital marketing — rather than selling a tool for your team to use. This is the option for a company without the commercial infrastructure to run these functions itself.

Certara sits partly outside this framework: its core business is quantitative drug-development software (biosimulation, PK/PD modeling) used for regulatory submissions, with a market-access and real-world-evidence consulting practice extending into commercial questions like pricing and payer evidence. It's the vendor to consider when your commercial question is downstream of a regulatory or scientific one.

Where you are in the launch lifecycle

A pre-launch biotech with no commercial infrastructure has a different problem than an established manufacturer optimizing an existing field force. EVERSANA and Beghou both explicitly serve companies preparing for a first commercial launch — EVERSANA by running the function, Beghou by consulting on launch planning, sales-force sizing and forecasting alongside its platform. Aktana assumes the opposite: an existing CRM and field force that a decision-support layer can make more effective. ZS spans both ends, serving large and mid-size biopharma commercial and market-access teams whether the question is launch design or ongoing optimization. Certara's relevance often starts even earlier, at the regulatory-submission stage, before a commercial launch plan exists at all.

Build the data or buy the analysis

A related question is whether you already have the underlying data these platforms would analyze. ZS is explicit that it sells analytical services and decision models built on top of data you already own or separately license, not the datasets themselves. Symphony Health is the opposite: its value is the claims and prescriber dataset itself, positioned against data-first competitors like IQVIA. If you don't yet have a source of prescriber-level or claims data, that's a prerequisite decision before a consulting-and-platform vendor like ZS or Beghou can do much for you.

How pricing works

Every vendor here is quote-only — consulting engagements, platform modules, and (for Symphony Health) data licenses are all priced through direct negotiation with no public rate card. Because the business models differ so much, ask each vendor to itemize what's software, what's data, and what's professional-services time; a consulting-plus-platform vendor's headline platform fee often understates the cost of the advisory work most clients actually buy alongside it.

Shortlist by situation

• If you have a mature CRM and field team and want AI-suggested next-best actions layered on top, look at Aktana.
• If you're an emerging or mid-size biopharma planning or managing a launch without a large in-house analytics team, look at Beghou Consulting.
• If you need quantitative modeling for regulatory submissions plus downstream pricing and market-access analysis, look at Certara.
• If you're a pre-launch or emerging biotech needing an outsourced commercial organization rather than software, look at EVERSANA.
• If you need claims-based prescriber targeting and market-share measurement as a licensed dataset, look at Symphony Health.
• If you're established commercial leadership wanting combined strategy consulting and analytics for go-to-market decisions, look at ZS.

Questions to ask vendors

• Are we buying software, a data license, consulting time, or outsourced execution — and can you itemize the split?
• If this sits on top of our CRM, what happens to the recommendations if our CRM data quality is poor?
• Where does the underlying data come from, how is market share or prescriber activity attributed, and how current is it?
• What does a typical engagement timeline look like from contract to first field-facing output?
• How is territory and incentive-compensation work validated for compliance with our legal and regulatory requirements?

Common mistakes

The most common mistake is buying a decision-support layer like Aktana before the CRM underneath it is mature enough to generate good segmentation and engagement data — the recommendations are only as good as what's already being captured. A second is hiring a full outsourced partner like EVERSANA for a problem that's really a discrete analytics gap a consulting engagement could close more cheaply, or the reverse: trying to build launch capability in-house when a company genuinely lacks any commercial infrastructure. A third is comparing a data vendor's price to a consulting-and-platform vendor's price as if they're the same purchase — one sells you data, the other sells you judgment applied to data, and conflating the two produces a bad comparison either way.

For more on the tools discussed here, read Beghou vs ZS and Aktana vs EVERSANA, or browse every tool in this category.